# A phase II study of leuprolide in advanced/recurrent endometrial cancer.

> PubMed lists PMID 8995560 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-01 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8995560-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8995560-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-8995560-leuprolide-v1.json
- Content SHA-256: `5319603f70bfc59ffe0560d9c115d27bdaf6081b3ad0ea2be96c2c86e9feefc1`

## Claims and source pins

### Headline

A phase II study of leuprolide in advanced/recurrent endometrial cancer. ([`pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828`](#source-pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828))

### Summary

PubMed lists PMID 8995560 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-01 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828`](#source-pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828))

### Paragraph 1

PubMed lists PMID 8995560 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-01 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828`](#source-pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828`](#source-pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828))

## Sources

<a id="source-pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828"></a>
- **A phase II study of leuprolide in advanced/recurrent endometrial cancer. · retained source version 1:2013-11-21:current:d245a72c68285a8a7baed582e1ba5641855eff1aaf78f888759d24d411412bad** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8995560/) (`pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "A phase II study of leuprolide in advanced/recurrent endometrial cancer." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-8995560-leuprolide-v1.json SHA-256: 5319603f70bfc59ffe0560d9c115d27bdaf6081b3ad0ea2be96c2c86e9feefc1.